---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000122"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:40:14.321184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M

## Summary
- Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.
- ZORYVE plaque psoriasis prescriptions over 110k from nearly 9k prescribers; FDA approved expanded indication to children ages 6+.
- sNDA submitted for roflumilast cream 0.15% for atopic dermatitis ages 6+; potential approval Q3 2024.
- Completed $100M public offering in Oct 2023; amended SLR debt facility removing market cap covenant, requires $31M additional capital by Apr 2024.
- Appointed Todd Edwards CCO and John Smither interim CFO; Huadong collaboration upfront $30M.

## SEC filing metadata
- accession: 0001787306-23-000122
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/0001787306-23-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/arqt-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000122
- JSON: https://secwatch.observer/filing/0001787306-23-000122.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000122.txt

## Key facts
- Earnings Releases
  Arcutis Biotherapeutics, Inc. reported quarter ended September 30, 2023 results: revenue net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million.
  - Period: quarter ended September 30, 2023
  - Revenue: net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million
  - Result: reported results
  source text: 2023 Financial Results and Provides Business Update • Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/0001787306-23-000122-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.